Liangyu Zeng
Overview
Explore the profile of Liangyu Zeng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
5
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cai W, Lu Y, He H, Li J, Liu S, Geng H, et al.
Oncol Lett
. 2024 Dec;
29(2):71.
PMID: 39628826
Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for diffuse large B-cell lymphoma (DLBCL). However, it may activate the systemic immune system of the patient, resulting in cytokine...
2.
Zhang Y, Geng H, Zeng L, Li J, Yang Q, Jia S, et al.
Hematol Oncol
. 2023 Sep;
42(1):e3227.
PMID: 37776326
Dual-targeted chimeric antigen receptor T (CAR-T) cell is an important strategy to improve the efficacy of CD19 CAR-T cell against refractory or relapsed B cell non-Hodgkin lymphoma (R/R B-NHL). However,...
3.
Geng H, Jia S, Zhang Y, Li J, Yang Q, Zeng L, et al.
Front Immunol
. 2023 Sep;
14:1219167.
PMID: 37671152
Introduction: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) shows poor response rates in non-germinal center B cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) patients with multiple extranodal involvement....
4.
Liu Y, Zhu Q, Tao Y, Zeng Y, Li S, Zeng L, et al.
iScience
. 2022 Nov;
25(12):105403.
PMID: 36419851
Our recent study has found that gut bacteria contributes to hypertension and upregulates lysophospholipase A1 (LYPLA1) in the renal medulla of rats. This work aimed to investigate the role of...